Retatrutide

Retatrutide (LY3437943) is the first triple-receptor agonist peptide to engage GLP-1, GIP and glucagon receptors from a single molecule. It sits at the cutting edge of metabolic and obesity research, and it is supplied through JCSG.org for United Arab Emirates laboratories as research-grade Body Pharm reference material. All retatrutide products on this page are for laboratory research use only — not for human or veterinary use.

Our peptides

Body Pharm Retatrutide 32 Pen — a 32-dose pen of retatrutide, the next-generation triple GLP-1/GIP/glucagon agonist, formatted for standard-duration in vitro and preclinical work.

Body Pharm Retatrutide 64 Pen — the extended 64-dose format doubles capacity for longitudinal metabolic research, reducing re-order cycles across multi-arm study designs.

Live AED pricing is shown in the buy box on each product page. No prices are quoted here to avoid staleness.

Key takeaways

• Retatrutide is a triple-receptor agonist (GLP-1R, GIPR, GCGR) — the most receptor-diverse incretin-class research peptide in late-stage development.
• The glucagon-receptor component adds energy-expenditure and hepatic-lipolysis pathways absent from approved dual and single agonists.
• Body Pharm retatrutide is supplied as research-grade reference material with a batch Certificate of Analysis.
• Retatrutide holds no marketing authorisation from any medicines regulator; it is an investigational compound and, for JCSG.org purposes, a laboratory reagent only.
• The Body Pharm Retatrutide 32 and 64 pens sit within the wider JCSG.org UAE metabolic-peptide range alongside NAD+ and MOTS-C.

What is retatrutide (LY3437943)?

Retatrutide is a synthetic peptide originally developed under the code LY3437943 and studied as a once-weekly subcutaneous investigational agent. It is the first molecule to simultaneously activate three incretin and metabolic receptors: GLP-1, GIP and glucagon. The "triple G" shorthand used across metabolic-research commentary refers to this tri-receptor profile.

Each receptor controls a distinct pathway. The GLP-1 receptor governs glucose-dependent insulin secretion and satiety signalling. The GIP receptor drives insulinotropic and adipose-modulating effects. The glucagon receptor (GCGR) controls hepatic glucose output and energy expenditure. Jastreboff and colleagues (NEJM, 2023) formally describe retatrutide as a triple-hormone-receptor agonist, engineered for full agonism at GLP-1R and GIPR and a moderated, partial-agonist profile at GCGR to capture thermogenic benefit without driving hyperglycaemia.

Structurally, retatrutide is a fatty-acid-modified peptide engineered for albumin binding and extended dosing intervals. A lysine-linked fatty acid side chain confers the albumin binding and the long half-life that supports weekly administration in the published trial protocols. It sits in the same long-acting pharmacokinetic class as dual and single incretin agonists, but with a wider receptor footprint.

Mechanism: why triple agonism matters

Retatrutide differs from dual agonists (which engage GLP-1R and GIPR) and single agonists (GLP-1R only) by adding partial agonism at the glucagon receptor. The mechanistic consequence is an added thermogenic and hepatic-lipolytic axis on top of the appetite-suppressing and insulinotropic effects shared across the incretin class.

Historically, glucagon-receptor agonism was avoided as a monotherapy because of hyperglycaemia risk. Co-agonism with GLP-1R is thought to neutralise that risk: insulin secretion stimulated by the GLP-1 arm, combined with glucagonostatic effects on alpha cells, offsets the glycaemic cost of GCGR signalling. The catabolic contribution of the glucagon arm can therefore be expressed as net lipid mobilisation rather than worsening glucose control. Glucagon signalling drives hepatic glucose output, increased resting energy expenditure, and mobilisation of hepatic and visceral lipid stores.

In the Phase 2 obesity cohort reported by Jastreboff et al. (NEJM, 2023), dose-cohort means tracked a clear dose-response signal, and weight-loss curves at the highest doses had not plateaued at the 48-week observation point. Later topline Phase 3 data extended that signal across longer observation windows, though full peer-reviewed publication continues to mature. These are supervised clinical-trial findings and cannot be extrapolated to research-grade reference material.

What researchers study

Research-grade retatrutide is reference material for laboratory use, distinct in every regulatory and quality-assurance sense from a licensed medicinal product. For laboratories with appropriate ethics and biosafety cover, LY3437943 reference material supports a defined set of experiments:

• Competitive radioligand or fluorescent binding assays at human GLP-1R, GIPR and GCGR.
• Cyclic AMP (cAMP) accumulation and beta-arrestin recruitment assays in HEK293 or CHO lines stably expressing each receptor.
• Comparative dose-response profiling against other incretin-class agonists.
• Computational or cell-based metabolic pathway modelling interrogating balanced tri-agonism.

Because retatrutide is the first clinical-stage agent where GCGR partial agonism is deliberately retained, it is a useful probe for separating the glucagon-driven, energy-expenditure arm of metabolic signalling from the GLP-1/GIP-driven satiety and insulinotropic arms. Researchers designing multi-arm work often cross-reference the mitochondrial and metabolic peptides in the JCSG.org catalogue, including the NAD+ and MOTS-C research overviews, where AMPK and sirtuin signalling intersect with incretin biology in preclinical models.

The Body Pharm retatrutide pens

Two formats are stocked for UAE researchers:

Format	Capacity	Suits
Body Pharm Retatrutide 32 Pen	32 doses	Standard-duration in vitro and preclinical arms
Body Pharm Retatrutide 64 Pen	64 doses	Longitudinal or multi-arm metabolic studies

The 64-dose format doubles capacity per device, which matters for longitudinal study designs: fewer re-order cycles, a single lot number across a longer study, and reduced batch-to-batch variability. The 32-dose pen suits shorter windows and dose-ranging arms where a smaller reserve is sufficient.

Before ordering either pen, insist on the batch-specific documentation: an HPLC trace, mass-spectrometry identity confirmation, residual solvent data, and an endotoxin result on the Certificate of Analysis, each cross-referenced to the vial or pen batch number. Body Pharm CoA details are listed on the product page.

Handling and storage

Retatrutide reference material is a peptide reagent and should be handled as such. Lyophilised or pre-mixed stock is held cold; pre-mixed pen solution is typically kept refrigerated at 2–8 °C, protected from light, and should not be frozen once in the liquid state. Treat any per-actuation concentration as a value to confirm against the supplier datasheet rather than assume from the product page, and log the lot number and CoA reference in the institutional reagent register for traceability.

Store working material away from direct light and moisture, avoid unnecessary temperature cycling, and record chain-of-custody against the receiving institution's standard operating procedures.

Regulatory context in the UAE

Retatrutide holds no marketing authorisation from any medicines regulator as an approved therapy, and it cannot lawfully be presented, prescribed or administered as a medicine. For JCSG.org purposes it is supplied strictly as a research chemical for in vitro and preclinical laboratory use.

Peptide importation and domestic distribution in the UAE fall under the relevant national health-authority oversight, which regulates pharmaceuticals and related substances under category-level frameworks rather than a peptide-specific schedule. Research-use or free-zone labelling does not exempt an entity from that oversight or from customs review. Procurement officers should confirm classification with their institutional compliance officer before raising a purchase order and retain the commercial invoice, packing list, Certificate of Analysis and safety data sheet against the shipment. This page is not legal advice.

Range placement

Within the JCSG.org UAE catalogue, retatrutide is the lead metabolic and obesity-research peptide. It sits alongside mitochondrial and energy-metabolism compounds such as NAD+ and MOTS-C, and near the growth-hormone-axis peptides CJC-1295, ipamorelin and tesamorelin. Tissue-repair tools BPC-157 and TB500 round out the research panel a UAE laboratory can source under a single procurement record.

Frequently asked questions